



Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION BY APPLICANT</b> <i>(Use several sheets if necessary)</i>	DOCKET NUMBER 100507 - 1 APPLICANT AstraZeneca AB	US APPLICATION NUMBER 10/051,776
	FILING DATE January 16, 2002	GROUP ART UNIT 1614

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

/ Gaster, et al., "The Selective 5-HT<sub>1B</sub> Receptor Inverse Agonist 1'-Methyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo" *J. Med. Chem.*, 41, 1218-1235 (1998)

/ Russell, et al., "3-[3-(Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT<sub>1D</sub> Receptor Agonists", *J. Med. Chem.*, 42, 4981-5001, (1999)

/ Barnes, et al., "A review of central 5-HT receptors and their function", *Neuropharmacology* 38, 1083-1152, (1999)

/ Massot, et al., "5-HT1B Receptors: A Novel Target for Lithium", *Neuropsychopharmacology* Vol. 21, No. 4, 530-541

/ Halazy, et al., "5-HT<sub>1B/1D</sub> antagonists and depression", *Exp. Opin. Ther. Patents*, 7(4) 339352 (1997)

/ Cryan et al., "5-HT<sub>1A</sub> and Beyond: The Role of Serotonin and its Receptors in Depression and the Antidepressant Response", *Hum. Psychopharmacol. Clin. Exp.*, 15, 113-135 (2000)

**EXAMINER**

**DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.